Skip to content

    Leukemia & Lymphoma

    Font Size

    This May Boost Leukemia Stem Cell Transplant

    Study showed many were able to avoid graft-versus-host disease

    WebMD News from HealthDay

    By Steven Reinberg

    HealthDay Reporter

    WEDNESDAY, Jan. 6, 2016 (HealthDay News) -- People with acute leukemia who were given antibody therapy before a stem cell transplant fared better than those who didn't receive the treatment, a small study found.

    Stem cell transplantation allows doctors to give higher doses of cancer-killing chemotherapy, according to the American Cancer Society. However, the odds of the body rejecting the transplanted stem cells are very high -- a condition called graft-versus-host disease, the study authors explained.

    By treating patients first with animal-derived antibodies, called antihuman T-lymphocyte immune globulin (ATG), the researchers were able to lower the threat of rejection in patients.

    "Graft-versus-host disease is the most serious complication after stem cell transplantation," said lead researcher Dr. Francesca Bonifazi, from the Institute of Hematology at Bologna University in Italy.

    "Using [ATG] reduces the risk of complications of stem cell transplants without increasing the risk of leukemia recurrence and infections," she added.

    After an average follow-up of two years, 32 percent of the patients given ATG had chronic graft-versus-host disease. But, almost 69 percent of patients who weren't given ATG had graft-versus-host disease, Bonifazi said.

    "Stem cell transplantation is a curative option for several blood diseases and for acute leukemia in particular, which represents the most frequent indication for transplant," she said.

    "The risk of severe complications that can be life-threatening or severely affect the quality of life can be significantly reduced without decreasing transplant efficacy," Bonifazi said.

    The findings was published Jan. 7 in the New England Journal of Medicine.

    The study included 168 leukemia patients treated at 27 different centers. The volunteers were randomly assigned to receive ATG or not.

    At two years, the survival rate was similar in patients who received ATG or didn't. But, the rate of survival in which they were free from chronic graft-versus-host disease and cancer recurrence was significantly better among patients given the antibody -- 37 percent versus 17 percent, the researchers found.

    "Here, by using [ATG] prior to transplant, we show that the risk of chronic graft-versus-host disease is significantly reduced without an increase of cancer relapse," said study co-author Dr. Nicolaus Kroger. He is director of the department of stem cell transplantation at University Hospital Hamburg-Eppendorf in Hamburg, Germany.

    Today on WebMD

    stem cells
    What are they and why do we need them?
    Lung cancer xray
    See it in pictures, plus read the facts.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Ovarian cancer illustration
    Do you know the symptoms?
    Vitamin D
    New Treatments For Non-Hodgkins Lymphoma
    Lifestyle Tips for Depression Slideshow
    Pets Improve Your Health